VEA
RCUS icon

Virtus ETF Advisers’s Arcus Biosciences RCUS Stock Holding History

Virtus ETF Advisers’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-4,143
Closed -$61.7K – 712
2024
Q4 		$61.7K Sell
4,143
-1,281
-24% -$20.9K 0.03% 441
2024
Q3 		$82.9K Buy
5,424
+99
+2% +$1.56K 0.04% 411
2024
Q2 		$81.1K Buy
5,325
+414
+8% +$6.68K 0.04% 401
2024
Q1 		$92.7K Sell
4,911
-340
-6% -$5.88K 0.05% 375
2023
Q4 		$100K Buy
5,251
+209
+4% +$3.34K 0.06% 358
2023
Q3 		$90.5K Sell
5,042
-506
-9% -$10.2K 0.06% 347
2023
Q2 		$113K Buy
5,548
+2,538
+84% +$48.3K 0.07% 340
2023
Q1 		$54.9K Sell
3,010
-1,156
-28% -$22.1K 0.03% 427
2022
Q4 		$86.2K Sell
4,166
-902
-18% -$24.8K 0.05% 442
2022
Q3 		$133K Buy
5,068
+39
+0.8% +$1.03K 0.05% 372
2022
Q2 		$127K Buy
5,029
+1,075
+27% +$26.3K 0.05% 365
2022
Q1 		$125K Sell
3,954
-225
-5% -$7.54K 0.06% 256
2021
Q4 		$169K Sell
4,179
-4,485
-52% -$174K 0.06% 291
2021
Q3 		$302K Sell
8,664
-447
-5% -$13.9K 0.13% 200
2021
Q2 		$250K Sell
9,111
-237
-3% -$6.77K 0.1% 210
2021
Q1 		$262K Buy
9,348
+160
+2% +$5.57K 0.11% 278
2020
Q4 		$239K Sell
9,188
-1,887
-17% -$45.7K 0.1% 326
2020
Q3 		$190K Sell
11,075
-1,524
-12% -$34K 0.1% 303
2020
Q2 		$312K Buy
+12,599
New +$340K 0.15% 295
2018
Q4 		– Sell
-28,669
Closed -$400K – 367
2018
Q3 		$400K Sell
28,669
-21,065
-42% -$269K 0.04% 162
2018
Q2 		$609K Buy
+49,734
New +$780K 0.54% 131

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return

Virtus ETF Advisers's RCUS Position: Q1 2025 in Review

Virtus ETF Advisers sold out of Arcus Biosciences (RCUS) in Q1 2025, closing a stake of 4,143 shares — an estimated $61.7K sold.

Virtus ETF Advisers first reported a position in RCUS in Q2 2018 and held it in 21 quarters. The position peaked at $609K in Q2 2018. 186 funds tracked by Wall St. Rank hold RCUS as of Q1 2025.

  • Virtus ETF Advisers reported no remaining Arcus Biosciences position as of Q1 2025 after selling out during the quarter.
  • Virtus ETF Advisers sold 4,143 Arcus Biosciences shares in Q1 2025, an estimated $61.7K.
  • Virtus ETF Advisers first reported a position in Arcus Biosciences in Q2 2018 and held it in 21 quarters.
  • Virtus ETF Advisers's Arcus Biosciences position peaked at $609K in Q2 2018.
  • 186 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2025.

Based on Virtus ETF Advisers's 13F filing for Q1 2025, filed 14 May 2025.